Boston Scientific

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Aug 24

Updated

11 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

2.7%

7D

-5.1%

Loading

1Y

2.7%

7D

-5.1%

You can edit this narrative until Dec 12 12:05 PM. Then, changes will post as Updates.

Author's Valuation

US$126.4826.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum

Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.

Shared on 27 Nov 25

BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum

Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.

Shared on 07 Nov 25

Fair value Increased 0.27%

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.

Shared on 24 Oct 25

Fair value Increased 1.29%

Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.

Shared on 07 May 25

Fair value Increased 7.78%

Shared on 30 Apr 25

Fair value Decreased 3.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 0.42%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 16 Apr 25

Fair value Decreased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.47%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 0.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 1.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$126.48

26.8% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

10.02%

Medical Equipment revenue growth rate

8.48%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.87%

Calculation

US$5.12b

Earnings '28

x

46.55x

PE Ratio '28

=

US$238.53b

Market Cap '28

US$238.53b

Market Cap '28

/

1.50b

No. shares '28

=

US$158.74

Share Price '28

US$158.74 Share Price '28

Discounted to 2025 @ 7.88% p.a.

=

US$126.43

Fair Value '25